- Home
- GOCO vs ZURA Comparison
GOCO vs ZURA Comparison
Compare GOCO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- ZURA
- Stock Information
- Founded
- GOCO 2001
- ZURA 2022
- Country
- GOCO United States
- ZURA United States
- Employees
- GOCO N/A
- ZURA N/A
- Industry
- GOCO Specialty Insurers
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOCO Finance
- ZURA Health Care
- Exchange
- GOCO Nasdaq
- ZURA Nasdaq
- Market Cap
- GOCO 64.9M
- ZURA 69.9M
- IPO Year
- GOCO 2020
- ZURA N/A
- Fundamental
- Price
- GOCO $5.67
- ZURA $1.05
- Analyst Decision
- GOCO Hold
- ZURA Buy
- Analyst Count
- GOCO 1
- ZURA 7
- Target Price
- GOCO $18.00
- ZURA $14.33
- AVG Volume (30 Days)
- GOCO 67.1K
- ZURA 755.8K
- Earning Date
- GOCO 08-07-2025
- ZURA 08-08-2025
- Dividend Yield
- GOCO N/A
- ZURA N/A
- EPS Growth
- GOCO N/A
- ZURA N/A
- EPS
- GOCO N/A
- ZURA N/A
- Revenue
- GOCO $834,266,000.00
- ZURA N/A
- Revenue This Year
- GOCO $8.51
- ZURA N/A
- Revenue Next Year
- GOCO $7.19
- ZURA N/A
- P/E Ratio
- GOCO N/A
- ZURA N/A
- Revenue Growth
- GOCO 13.18
- ZURA N/A
- 52 Week Low
- GOCO $5.01
- ZURA $0.97
- 52 Week High
- GOCO $21.00
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- GOCO 45.31
- ZURA 48.12
- Support Level
- GOCO $5.45
- ZURA $1.10
- Resistance Level
- GOCO $6.01
- ZURA $1.22
- Average True Range (ATR)
- GOCO 0.47
- ZURA 0.09
- MACD
- GOCO 0.14
- ZURA 0.00
- Stochastic Oscillator
- GOCO 44.63
- ZURA 31.25
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.